Presentation Type
Poster
Discipline Track
Community/Public Health
Abstract Type
Research/Clinical
Abstract
Background: The therapeutic application of microRNA(s) in the field of cancer has generated significant attention in research. miR-205 is a tumor suppressor in various cancers. However, the delivery of miR-205 is an unmet clinical need. Thus, the development of liposomal formulation platform to deliver miR-205 is highly sought. The most common applications of liposome formulations are vaccines and anticancer formulations (e.g., mRNA, small molecule drugs). However, large-scale production with precise control of size and size distribution of the lipid-based drug delivery systems (DDSs) is one of the major challenges in the pharmaceutical industry. The objective of this study is to develop liposomal formulation with precise size and optimal for delivery of miR-205.
Methods: Microfluidics chip designed based on commercial microfluidic device platform was employed for preparation of liposomes. The device is set for the synthesis of liposome at total flow rate (FRR) 10 ml min−1 and 1:3 flow rate ratio (TFR). To determine the optimal conditions, the effect of different factors including FRR, TFR, and total lipid concentration (lipid and cholesterol) on particle size and size distribution is investigated. Liposomes are also produced by a bulk method to compare the properties of the liposomes formed through these methods. The obtained formulations were tested to analyses different physiochemical properties (DLS, FTIR, DSC, and TGA), stability studies and optimized liposomal formulation was confirmed by examining the intracellular accumulation.
Results: All formulations displayed an average size less than 200 nm and exhibited acceptable physicochemical behavior. This design demonstrated high productivity and better control of liposome size and polydispersity index (PDI) than conventional liposome preparation methods. The microfluidic devices were used to produce miR-205-loaded liposomes under different processing conditions which were later characterized and studied in vitro to evaluate their efficiency as a drug delivery system.
Conclusions: The obtained results demonstrated that the liposomes can effectively deliver miR-205 into cancer cells. Therefore, the microfluidic devices platform are promising devices for reproducible and scalable manufacturing of liposomal formulation.
Academic/Professional Position
Undergraduate
Mentor/PI Department
Immunology and Microbiology
Recommended Citation
Herrera, Victoria; Tiwari, Rahul; Kolli, Meghana; Chauhan, Neeraj; Kumar Ghali, Eswara Naga Hanuma; Chauhan, Subhash C.; and Yallapu, Murali, "Development of liposomes using microfluids for delivery of miR-205" (2024). Research Symposium. 24.
https://scholarworks.utrgv.edu/somrs/2024/posters/24
Included in
Development of liposomes using microfluids for delivery of miR-205
Background: The therapeutic application of microRNA(s) in the field of cancer has generated significant attention in research. miR-205 is a tumor suppressor in various cancers. However, the delivery of miR-205 is an unmet clinical need. Thus, the development of liposomal formulation platform to deliver miR-205 is highly sought. The most common applications of liposome formulations are vaccines and anticancer formulations (e.g., mRNA, small molecule drugs). However, large-scale production with precise control of size and size distribution of the lipid-based drug delivery systems (DDSs) is one of the major challenges in the pharmaceutical industry. The objective of this study is to develop liposomal formulation with precise size and optimal for delivery of miR-205.
Methods: Microfluidics chip designed based on commercial microfluidic device platform was employed for preparation of liposomes. The device is set for the synthesis of liposome at total flow rate (FRR) 10 ml min−1 and 1:3 flow rate ratio (TFR). To determine the optimal conditions, the effect of different factors including FRR, TFR, and total lipid concentration (lipid and cholesterol) on particle size and size distribution is investigated. Liposomes are also produced by a bulk method to compare the properties of the liposomes formed through these methods. The obtained formulations were tested to analyses different physiochemical properties (DLS, FTIR, DSC, and TGA), stability studies and optimized liposomal formulation was confirmed by examining the intracellular accumulation.
Results: All formulations displayed an average size less than 200 nm and exhibited acceptable physicochemical behavior. This design demonstrated high productivity and better control of liposome size and polydispersity index (PDI) than conventional liposome preparation methods. The microfluidic devices were used to produce miR-205-loaded liposomes under different processing conditions which were later characterized and studied in vitro to evaluate their efficiency as a drug delivery system.
Conclusions: The obtained results demonstrated that the liposomes can effectively deliver miR-205 into cancer cells. Therefore, the microfluidic devices platform are promising devices for reproducible and scalable manufacturing of liposomal formulation.